United States
Print page content Print
Increase text size Decrease text size
Text Size



WEST NILE-INNOVATOR® vaccines aid in the prevention of West Nile; equine encephalomyelitis due to Eastern, Western and Venezuelan viruses; and tetanus. WEST NILE-INNOVATOR is the veterinarian’s first choice for core disease protection and has been shown to provide an immune response to West Nile virus that is four times more than a big one-shot combination vaccine.1,2

        Video: West Nile Virus - A Continuing Risk

West Nile virus is fatal in 33% of horses that exhibit clinical signs of disease.3 Vaccination is the most effective way to help protect horses against West Nile virus and other mosquito-borne diseases, such as Eastern equine encephalitis (EEE) and Western equine encephalitis (WEE). If vaccinated, horses have shown to be 30 times less likely to contract West Nile virus.4

Vaccinate with WEST NILE-INNOVATOR – no other vaccine has helped protect more horses.1

WEST NILE-INNOVATOR vaccines contain the adjuvant MetaStim®, which is designed for safe, enhanced presentation of antigens to the horse’s immune system. MetaStim features a dual-phase formulation shown to stimulate both cell-mediated and humoral immunity to West Nile virus.5,6 Only INNOVATOR vaccines from Zoetis are adjuvanted with MetaStim for improved immune response.

To ensure peace of mind, all products within the WEST NILE-INNOVATOR and FLUVAC INNOVATOR® lines of vaccines from Zoetis are covered under the Equine Immunization Support Guarantee, which is the most comprehensive equine vaccine guarantee available. Under the Equine Immunization Support Guarantee, if a horse, properly vaccinated by a veterinarian, contracts the corresponding equine disease, Zoetis will reimburse the horse owner up to $5,000 in diagnostic and treatment costs.

Expand All

    • Has been shown to provide an immune response to West Nile virus that is four times more than a big one-shot combination vaccine.2
    • WEST NILE-INNOVATOR vaccine was shown to be 96.7% effective against a 2003 outbreak among immunologically naïve horses.4
    • The only vaccine credited for helping reduce the number of equine West Nile virus cases by nearly 70% from 2002 to 2003.7


    • The only West Nile virus vaccine adjuvanted with MetaStim for improved immune response.
    • Helps stimulate fast, antigen-specific cell-mediated and humoral responses against West Nile virus.5,6
    • Four combinations of WEST NILE-INNOVATOR allow a tailored fit for any vaccination program.
    • Ready to use; no reconstitution required.
    • Inject 1-mL dose intramuscularly to healthy horses 10 months of age or older using aseptic technique. Administer a second 1-mL dose three to six weeks after the first dose in unvaccinated or naïve horses.
    • A 1-mL revaccination should be given annually in previously vaccinated horses.
    • Always read and follow label indications.
    • Early revaccination may be advisable when horses are faced with an outbreak or with other conditions that might make exposure likely.

    Store in the dark at 2° to 7° C (35° to 45° F). AVOID FREEZING. SHAKE WELL. Use entire contents when first opened. In some instances, transient local reactions may occur at the injection site. Do not vaccinate within 21 days before slaughter. In case of anaphylactoid reaction, administer epinephrine. Thimerosal, neomycin and polymyxin B are added as preservatives. For veterinary use only.

  • 1 Data on file, MDI sales data for WEST NILE-INNOVATOR as of 12/31/15, Zoetis LLC.

    2 Cortese V, Hankins K, Holland R, et al. Serologic responses of West Nile virus seronegative mature horses to West Nile virus vaccines. J Equine Vet Sci. 2013;33:1101-1105.

    3 Core Vaccination Guidelines. American Association of Equine Practitioners website. http://www.aaep.org/-i-165.html. Accessed May 16, 2016.

    4 Epp T, Waldner C, West K. Efficacy of vaccination for West Nile virus in Saskatchewan horses, in Proceedings. 51st Annual Convention of the American Association of Equine Practitioners 2005;180-182.

    5 Davis EG, Zhang Y, Tuttle J, et al. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine. Vet Immunol Immunopathol. 2008;126(3-4):293-301.

    6 Davis EG, Bello NM, Bryan AJ, et al. Characterisation of immune responses in healthy foals when a multivalent vaccine protocol was initiated at age 90 or 180 days. Equine Vet J. 2014. doi:10.1111/evj.12350.

    7 2003 Equine West Nile Virus Outlook for the United States. APHIS Info Sheet. Fort Collins, CO: U.S. Department of Agriculture; 2003.